Physician profile
Mark Lyell
NPI 1407861776
$3,683.54
in general payments reported to CMS, 2019-2025
43 companies · $1,221 in 2025
The $1,221 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $391 · 2020: $33.41 · 2021: $101 · 2022: $333 · 2023: $282 · 2024: $1,323 · 2025: $1,221.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,758 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,757.80 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $960.28 | 2019-2025 | Erleada, Akeega, Balversa |
| Urogen Pharma, INC. | $324.74 | 2021-2025 | Jelmyto |
| Astellas Pharma US INC | $283.12 | 2019-2025 | Xtandi |
| Sumitomo Pharma America, INC. | $211.62 | 2024-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $195.15 | 2020-2025 | |
| Procept Biorobotics Corporation | $176.46 | 2024 | Aquabeam System |
| Immunitybio, INC. | $152.53 | 2024 | |
| Endo USA, INC. | $133.06 | 2024-2025 | Xiaflex, Aveed |
| Coloplast Corp | $112.58 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $78.86 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $70.26 | 2024-2025 | Adstiladrin |
| Teleflex LLC | $66.22 | 2022-2025 | Urolift |
| Merck Sharp & Dohme LLC | $65.49 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Davol INC. | $64.03 | 2022-2024 | Arista Ah Flexitip |
| Endo Pharmaceuticals INC. | $63.05 | 2021-2024 | Xiaflex, Aveed, Edex |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$14,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lyell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.